Venture Capital

With strong clinical data for its Dayspring system, Koya Medical is pitching to investors to fund the next phase of growth for its patient-centered tech.

A new $1 million business grant competition funded by the volatile $TRUMP meme coin blends 'America First' politics with a disruptive, equity-free model.

FortuneX Acquisition Corp. raised $75M in its IPO, but it enters a SPAC market wary of past failures and facing stricter regulatory oversight.

ConnectWise’s 2026 PitchIT cohort signals a major shift towards AI and automation, providing a launchpad for startups shaping the next era of managed services.

With new funding from top investors, Alacriti is set to accelerate its push into AI, fraud prevention, and programmable money for financial institutions.

Dnotitia has open-sourced its Agent Knowledge Base, a platform that goes beyond simple RAG to create a dynamic, learning memory for enterprise AI agents.

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

A Miami investment firm made a massive 3.86x return in 8 months by betting that power, not chips, was the real constraint on the AI industry's growth.

NextNRG reports a 56% revenue surge driven by AI-optimized fueling, but a closer look reveals a high-stakes bet on future energy infrastructure.

At the Louvre, Web3's most promising startups pitch to VCs managing billions. Discover the event forging the industry's next unicorns.

Fintech platform Relay secures $50M from General Catalyst to tackle small business cash flow crises. Here’s what it means for a struggling Main Street.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

With backing from Bain Capital and Armistice, the life sciences firm's latest offering aims to fund its push to automate pharmaceutical quality control.

An upcoming Singapore conference reveals how litigation finance is becoming a multi-billion dollar asset class, with Asia as its new, rapidly expanding frontier.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.